Nordeloz (Zoledronic Acid)

Zoledronic acid, the active ingredient in Nordeloz, is a bisphosphonate presented as an intravenous solution for infusion use. It is employed to treat conditions characterized by excessive bone resorption, such as osteoporosis, Paget's disease, bone metastases and malignant hypercalcemia. GNH USA supplies Nordeloz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nordeloz is a bisphosphonate that acts on diseases involving increased bone turnover.

- Osteoporosis: reduces the risk of vertebral and hip fractures by inhibiting osteoclast‑mediated bone loss. - Paget's disease of bone: normalises abnormal bone remodeling and alleviates bone pain. - Bone metastases: limits skeletal‑related events and pain in patients with cancer spread to bone. - Hypercalcemia of malignancy: lowers elevated serum calcium levels by suppressing bone resorption.

Adverse reactions may occur following intravenous administration of zoledronic acid.

Common Side Effects: - Acute phase reaction: fever, myalgia and flu‑like symptoms. - Nausea or vomiting. - Transient hypocalcaemia.

Serious or Rare Side Effects: - Osteonecrosis of the jaw. - Atypical femur fracture. - Severe renal impairment or acute kidney injury. - Anaphylactic or severe hypersensitivity reactions.

Before initiating therapy, certain safety measures should be observed.

- Renal function assessment: evaluate creatinine clearance and adjust use in renal impairment. - Calcium and vitamin D supplementation: ensure adequate levels to reduce hypocalcaemia risk. - Serum calcium monitoring: check levels before and after infusion. - Hypersensitivity: discontinue if signs of severe allergic reaction appear. - Elderly patients: use with caution due to increased susceptibility to renal and electrolyte disturbances. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Zoledronic acid may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant nephrotoxic agents (e.g., aminoglycosides, amphotericin B) may worsen renal toxicity. - Other bisphosphonates: combined use can increase risk of oversuppression of bone turnover. - High‑dose vitamin D supplements: may precipitate severe hypercalcaemia.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal function. - Corticosteroids: can exacerbate bone loss, requiring closer monitoring. - Loop diuretics: may influence calcium balance and renal clearance.